is glp 1 safe with kidney disease Recommendations for SGLT2i versus GLP-1 RA on the basis of GLP-1 Receptor Agonists and Kidney
Description
This is not just medication
Despite the rates of success, about 15% of people will not see clinically relevant weight loss
Glucagon-like peptide-1 receptor agonists, aka GLP-1 drugs, were originally approved and used for treatment of Type 2 diabetes, with the first product debuting in 2005
To determine the effects of diet or Fc-GLP-1 treatment, one-way ANOVA or Kruskal-Wallis followed by a Bonferroni or Dunns test, respectively, was carried out
